6. Parkinson disease Clinical trials / Disease details


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04332276
(ClinicalTrials.gov)
September 18, 202025/3/2020Dopaminergic restauratIon by intraVEntriculaire AdministrationA New Concept of Continuous Dopaminergic Stimulation by Cerebroventricular Administration of A-dopamine (Dopamine Stored in Anaerobia) for Severe Motor Fluctuations in Parkinson's Disease?Parkinson DiseaseDrug: A-dopamine;Drug: optimized oral treatmentUniversity Hospital, LilleInBrain PharmaRecruiting45 Years75 YearsAll20Phase 1/Phase 2France
2EUCTR2020-000155-12-FR
(EUCTR)
12/05/202014/01/2020Dopaminergic restauratIon controlled by intraventriculaire administrationA new concept of continuous dopaminergic stimulation by cerebroventricular administration of A-dopamine (dopamine stored in anaerobia) for severe motor fluctuations in Parkinson’s disease? - DIVE-I Proof of concept study: prospective, monocentric, controlled randomized study according a cross over design with 2 groups: cerebroventricular administration of A-dopamine versus optimized oral treatment in patients with Parkinson’s disease at the stage of severe motor complications related with oral L-dopa (fluctuations and dyskinesia). ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Solution de chlorhydrate de dopamine anaérobie
Product Code: A-dopamine
InBrain Pharma SASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 1;Phase 2France